Field Trip Psychedelics completes GLP synthesis of FT-104

Closely-held Field Trip Psychedelics successfully completed GLP synthesis of its psychedelic molecule, FT-104.

FT-104 is a new chemical substance designed to be a commercially viable alternative to naturally derived substances such as psilocybin, DMT and LSD.

The company noted that a preliminary assessment from in vitro and in vivo tests confirms the activity of FT-104 at the 5HT2A receptor, which is believed to be responsible for psychedelic experiences.

“The successful GLP synthesis of FT-104, along with confirmation of 5HT2A agonism, is a significant milestone for our drug development efforts through Field Trip Discovery,” Dr. Nathan Bryson, Field Trip’s CSO, said in a statement.

“It validates many of the hypotheses we had for FT-104 and positions us well to continue to advance this molecule through the rest of our preclinical work and into Phase 1 trials, which we expect to commence later next year,” he added.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.